Treatment of acute bronchiolitis with Chinese herbs

Xiao-Tang Kong, H T Fang, G Q Jiang, S Z Zhai, D L O'Connell, D R Brewster

Abstract

In a randomised single blind trial the Chinese herbs *Shuang Huang Lian* were evaluated for the treatment of acute bronchiolitis. Children with acute bronchiolitis and serological evidence of recent respiratory syncytial virus infection were studied in a tertiary hospital in Harbin, China. The 96 children were randomised into three treatment groups: herbs, herbs with antibiotics, and antibiotics alone. The herbs were prepared by the medical school pharmacy and administered daily by intravenous infusion for seven days. The main outcomes, assessed blindly, were symptomatic improvement in cough, fever, wheezing, chest signs, and duration of stay in hospital.

The mean duration of symptoms from the start of treatment was 6.2 (confidence interval 5.6 to 6.9) days in the two groups treated with herbs compared with 8.6 (confidence interval 7.5 to 9.8) days in the group treated with antibiotics alone. The mean reductions in duration of clinical manifestations for treatment with antibiotics alone compared with herbs were: from 3.1 to 1.5 days for fever, 9.1 to 6.1 days for cough, 6.5 to 4.1 days for wheezing, and 7.2 to 4.9 days for chest crackles. No adverse effect of *Shuang Huang Lian* herbal treatment was detected.

In conclusion, this study confirms Chinese experience with *Shuang Huang Lian* that it is safe and effective, and warrants further study.

(Arch Dis Child 1993; 68: 468-471)

Acute bronchiolitis is the most common serious respiratory infection in infancy, affecting one in 50 infants annually in industrialised countries.¹ The respiratory syncytial virus is responsible for over 80% of hospital admissions, with a peak incidence during the winter months.

Respiratory syncytial virus bronchiolitis is also an important problem in the developing world. A group of studies from 10 developing countries on the epidemiology of acute respiratory infections reported that the children studied spent an average of 22-40% of observed weeks with signs of acute respiratory infection, and had incidence rates for lower respiratory tract disease ranging from 0.2 to 8.1 new episodes per 100 child weeks at risk, with the highest incidence in children less than 18 months of age.² Although death rates for bacterial pneumonia are more than 50 times higher than for viral lower respiratory tract infections, the estimated number of deaths is only about 2.7 times higher for bacterial pneumonia.³ Respiratory syncytial virus is the most often identified agent in these studies, accounting for 15-20% of all viral pathogens, though mixed infections also occur.⁴⁻⁶

Oxygen and nursing care are the mainstays of hospital management of acute bronchiolitis.

There is no evidence that bronchodilators, corticosteroids, or antibiotics improve the course of the illness. Tribavirin (ribavirin) administered by aerosol has been shown to be effective,⁷ but its administration is complex and its role in treatment of patients outside an intensive care unit is still unclear. Thus, a new effective treatment for acute bronchiolitis could offer considerable benefits.

Traditional Chinese herbal treatments have come under increasing scrutiny in recent years, with particular interest in *qinghaosu* for malaria, and various herbs for such diverse disorders as eczema, malignancy, and fertility control. *Shuang Huang Lian* is a combination of traditional Chinese herbs used to treat respiratory tract infections. Although there has been research into its effects, there have been no randomised clinical trials. The present study was undertaken to test the hypothesis that *Shuang Huang Lian* is a safe and effective treatment of acute bronchiolitis.

Patients and methods

The study was carried out at the First Hospital of the Harbin Medical School from 1988 to 1989. Harbin is a large inland city in the northeast of China at 46°N latitude (equivalent to Milan or Montreal). Children admitted to this hospital with lower respiratory tract disease and serological evidence of respiratory syncytial virus infection, excluding those with underlying diseases such as congenital heart disease, were included in the study. Informed consent was obtained from the parents of all children in the study. The study was approved by the ethics committee of the Bureau of Traditional Medicine in Harbin.

Of 215 patients with a clinical diagnosis of acute lower respiratory tract infection admitted during the study period, 110 had serological evidence of respiratory syncytial virus infection by IgM antibody capture assay combined with enzyme linked immunosorbent assay.⁸⁻¹² Fourteen (13%) children had to be excluded due to refused parental consent. The remaining 96 children were randomly assigned to one of three treatment groups: (a) group A was treated with *Shuang Huang Lian* herbs; (b) group B with *Shuang Huang Lian* herbs and antibiotics; and (c) group C with antibiotics alone (no herbs).

There were 32 children in group A, 34 in group B, and 30 in group C. The design was single blind, so the clinical investigator assessing signs and symptoms twice daily was not aware of the treatment. Clinical signs were assessed exclusively by the investigator, whereas symptoms such as coughing and wheezing also relied on reports from nurses and parents. Blood was taken on admission for full blood count, serology, and determination of immunoglobulins.

First Hospital of Harbin
Medical University,
Harbin, China
X T Kong
H T Fang
G Q Jiang
S Z Zhai

University of Newcastle,
Department of
Paediatrics, John Hunter
Hospital, Locked Bag 1,
Hunter Region Mail
Centre, NSW 2310,
Australia
D R Brewster

University of Newcastle,
Centre for Clinical
Epidemiology and
Biostatistics, Newcastle,
Australia
D L O'Connell

Correspondence to:
Dr Brewster.

Accepted 12 November 1992

Table 1 Characteristics of the three groups before treatment

	A (Shuang Huang Lian) (n=32)	B (Shuang Huang Lian and antibiotics) (n=34)	C (antibiotics) (n=30)
Sex (M:F)	22:10	23:11	19:11
Median (range) age (months)	12 (3-48)	12 (5-36)	10 (2-48)
Mean (range) symptom duration (days before admission)	6.4 (1-20)	5.7 (2-18)	5.8 (2-15)
Severity of illness (mild:moderate:severe)*	11:15:6	12:16:6	12:13:5

*From Bruhn and Yeager.¹⁵

Shuang Huang Lian consists mainly of the three Chinese herbs *shuanghua*, *huangqin*, and *lianqiao*, which are derived from plants. *Shuanghua* is the flower bud of *Lonicera japonica*, *huangqin* is the root of *Scutellaria baicalensis*, and *lianqiao* is the fruit of *Forsythia suspensa*. The herbs were prepared for clinical use by the pharmaceutical factory of the First Hospital of Harbin Medical School.^{13 14} *Shuang Huang Lian* is received as a 20 ml ampoule for intravenous infusion, which is diluted in 100–200 ml 10% dextrose for administration. The dosage varies according to age (20 ml for patients under 6 months, 40 ml for 7–36 months, and 60 ml for patients over 36 months) and was administered over 30–60 minutes daily for seven days. The antibiotics used were either lincomycin 30 mg/kg/day or cephazolin 100 mg/kg/day intravenously daily for seven days in a similar manner to the *Shuang Huang Lian*. Aspirin was administered symptomatically for fever over 38.5°C, with no differences in use between the three treatment groups.

Odds ratios and 95% confidence intervals were calculated using the computer program Epi Info version 5. The geometric mean durations of signs and symptoms with 95% confidence intervals were calculated after log transformation.

Results

On admission, all 96 children in the study group had coughing, 91% were wheezing, 86% had chest crackles, 80% had chest wheezes, and 53% had fever. Using a modified severity score,¹⁵ 35 patients had mild disease, 44 moderate, and 17 severe. None of the patients required artificial ventilation, and there were no deaths. The median age of patients was 12 months; 22 were 0–6 months and 59 (61%) less than 12 months of age. As expected with respiratory syncytial virus infection in a hospital setting, there was a 2:1 male predominance and striking winter season-

ality. There were no important differences between treatment groups on entry into the trial (table 1).

The course of the illness was significantly shorter in groups A and B than in group C (table 2). No significant differences were detected between groups A and B, so they have been combined into the 'herbal' group with group C as 'non-herbal'. The mean duration of symptoms for herbal treatment was 6.2 (confidence interval 5.6 to 6.9) days compared with 8.6 (confidence interval 7.5–9.8) days in the non-herbal group. Furthermore, there were more children with an improvement in symptoms within two days of starting herbal treatment, and fewer with symptoms persisting for one week than in the non-herbal group (table 3). For example, after two days of treatment, patients treated with herbs were 4.0 times more likely to be coughing less and 13.2 times more likely to have an improvement in chest wheezes than the patients treated with antibiotics alone, and in the herbal patients it was only 0.19 and 0.11 times as likely for coughing and chest wheezes, respectively, to have persisted beyond seven days of treatment.

Chest radiographs were performed in 70 patients (73%), and showed no abnormalities in 11, hyperinflation in 12, increased lung markings in 37, and consolidation in 22, with no significant differences between treatment groups. The mean (range) haemoglobin on admission in herbal treated patients (groups A and B) was 124 g/l (95–165), with no abnormalities in white blood cell and differential counts. There were no significant differences in serum immunoglobulin concentrations in the acute phase or during convalescence between treatment groups, but overall IgM values were higher and IgG/IgA values lower than in controls without respiratory syncytial virus of the same age. No side effects or toxic reactions to *Shuang Huang Lian* were observed in the patients treated with herbs. Specifically, there was no pain or inflammation at the effusion site, no blood pressure changes during or immediately after the infusion, and no adverse effects on the children noted by parents or medical staff.

Discussion

Although *Shuang Huang Lian* is composed of three herbs, it has at least 29 known ingredients (table 4). *Huangqin* is known to enhance lymphocyte transformation and macrophage function, whereas *lianqiao* and *shuanghua* have anti-inflammatory actions. The combination of herbs in *Shuang Huang Lian* has been shown in animal studies to be antipyretic, a stimulant of respiration and gut peristalsis, and a myocardial depressant. It has also in vitro inhibitory activity against certain bacteria and viruses (influenza, parainfluenza, and respiratory syncytial virus, but not adenovirus) as well as in vivo effects against influenza in mice.¹⁶ As our study groups B and C received wide spectrum antibiotics, bacterial inhibition does not explain the effect of *Shuang Huang Lian* in this study. The exact mechanism of *Shuang Huang Lian* action is unclear, however. We can only speculate about the relative contributions of anti-inflammatory,

Table 2 Mean duration (days) of signs and symptoms after treatment. Results given as geometric mean days (95% confidence intervals)

Symptoms	A (Shuang Huang Lian)	B (Shuang Huang Lian and antibiotics)	C (antibiotics)
Fever (n=51)	1.5 (1.2 to 2.0)	1.9 (1.4 to 2.5)	2.7 (1.9 to 3.8)
Cough (n=96)	6.1 (5.3 to 6.9)	5.5 (4.8 to 6.3)	7.7 (6.7 to 8.9)
Wheezing (n=87)	4.2 (3.7 to 4.9)	4.0 (3.4 to 4.6)	6.1 (5.2 to 7.3)
Chest wheezes (n=77)	4.9 (4.0 to 5.9)	4.6 (3.8 to 5.6)	7.7 (6.7 to 8.9)
Chest crackles (n=83)	4.2 (3.5 to 5.1)	4.3 (3.6 to 5.2)	6.6 (5.6 to 7.8)
Any sign or symptom (n=96)	6.4 (5.6 to 7.3)	6.0 (5.0 to 7.1)	8.6 (7.5 to 9.8)
Hospital stay (n=96)	7.8 (7.0 to 8.6)	7.0 (6.3 to 7.8)	9.8 (8.8 to 11.0)

p<0.01 for groups AB combined v C, except for fever.

Note: the discrepancy with the abstract data is due to non-geometric mean data.

Table 3 Duration of clinical manifestations after treatment

	Herbal groups (A and B) (%)	No herbs (C) (%)	Odds ratio (95% confidence intervals)
Cough			
Improved by 2 days	38	13	4.0 (1.2 to 17.2)
Persisted more than 7 days	20	57	0.19 (0.07 to 0.53)
Wheeze			
Improved by 2 days	56	17	6.4 (2.0 to 23.6)
Persisted more than 7 days	4	35	0.14 (0.03 to 0.59)
Chest crackles			
Improved by 2 days	47	20	3.5 (1.2 to 11.9)
Persisted more than 7 days	17	62	0.16 (0.05 to 0.54)
Chest wheezes			
Improved by 2 days	48	7	13.2 (2.8 to 120.4)
Persisted more than 7 days	15	62	0.11 (0.03 to 0.39)

antiviral, immune enhancing, bronchodilator, or other unknown actions of *Shuang Huang Lian*. Further studies are needed to elucidate this question.

Shuang Huang Lian has been available as an intravenous preparation for the treatment of acute lower respiratory infections at the First Hospital in Harbin since 1973, and has been found to be clinically effective and free of toxic effects. This considerable clinical and laboratory experience with *Shuang Huang Lian* in China is not readily accessible in English, however. Xu Kai-jian *et al* measured the bioavailability of baicalin (the major component of *huangqin*) and chlorogenic acid (the major component of *shuanghua*) in 14 adults after treatment with *Shuang Huang Lian*.¹⁷ After administration by mouth, peak serum concentrations of 4–6 µg/ml were reached at six hours, and levels of around 2 µg/ml for each component persisted for two to eight hours after intravenous infusion. The lethal dose (LD₅₀) of *Shuang Huang Lian* injection from animal studies is 56.1 (7.1) ml/kg.

There are some features of respiratory syncytial virus infection in these Chinese children which differ from the typical disease seen in paediatric wards in Western countries. We believe that these differences are real and not just related to patient selection or diagnostic criteria. At the First Hospital in Harbin, bronchiolitis is a less acute illness which affects a slightly older age group, and patients present later to hospital and have a more prolonged disease course. Thus, our non-herbal group had symptoms for a mean of 15 days, including six days before admission. A Beijing study found respiratory syncytial virus in 47 (13%) of 364 acute respiratory admissions in children under 5 years, with 21 patients older than 12 months, and isolated adenoviruses from an additional 12% of patients with acute respiratory infection.¹⁸ A protracted clinical course of acute bronchiolitis has also been well documented in the UK.¹⁹

Table 4 Major known ingredients of *Shuang Huang Lian* herbs

<i>Shuanghua</i>	<i>Huangqin</i>	<i>Lianqiao</i>
Chlorogenic acid	Baicalin	Forsythol
Isochlorogenic acid	Baicalin	Rutin
Neochlorogenic acid	Neobaicalin	Oleanolic acid
Lutedolia	Wagonin	Forsythol
Caffeoylquinic acid	Wagonin	Volatile oil
Inositol	B-Sitosterol	Betulinic acid
Linalool	Anlylose	Urgolic acid
Resin	Oraxylin A	Triterpenoid saponin
Polysaccharide	Skullcapflavone	Cumarin
	Chrysin	Alkaloid

There is still considerable confusion and controversy over the use of the terms bronchiolitis, bronchitis, and asthma. We attempted to circumvent this by restricting our study to children with confirmed respiratory syncytial virus infection, but unfortunately the IgM antibody capture assay combined with enzyme linked immunosorbent assay is not as reliable for respiratory syncytial virus as antigen tests (for example, immunofluorescence) or tissue culture. Although this test is highly sensitive for respiratory syncytial virus, it may remain positive for several months after acute infection, so that positive IgM serology could reflect past infection in some of our patients. Furthermore, some patients would have been diagnosed as having asthma in a Western hospital, as there was a previous history of wheezing in 10 of the 96 children (10%). This could mean that *Shuang Huang Lian* benefits a wider spectrum of respiratory diseases than just respiratory syncytial virus infections. Nevertheless, the high prevalence of chest crackles and strong male predominance in our patients support respiratory syncytial virus bronchiolitis.

Finally, this was not a placebo controlled trial. Placebos were not considered acceptable in this cultural context, so intravenous antibiotic administration was used instead of a placebo in the non-herbal group and also in one of the groups treated with *Shuang Huang Lian*. Although ward staff and parents were not specifically blind to the study, the protocol for intravenous antibiotic treatment was similar to the herbal administration as once daily intravenous administration. The use of antibiotics as placebo could introduce a potential bias, as two studies have found antibiotics to be possibly detrimental in respiratory syncytial virus bronchiolitis.^{20,21} Our study design with three groups enables us to exclude this, however, as we found no differences between the groups treated with herbs and antibiotics (group B) and herbal only group (group A) (table 2).

In conclusion, the results of this study support the clinical experience with *Shuang Huang Lian* in the treatment acute bronchiolitis in China and show that it is safe and shortens the clinical course of the illness. We believe that the reductions in duration of symptoms in the patients treated with *Shuang Huang Lian* (tables 2 and 3) are clinically significant. Although the administration of *Shuang Huang Lian* intravenously in this study indicates its pharmacological potency, this method of treatment for seven days would limit its usefulness in a Western context where admission to hospital for bronchiolitis may last only a few days. Consequently, one of us (Kong) is currently studying its administration as a nebulised solution, and preliminary results from Beijing Children's Hospital suggest that it is equally effective by this route. We believe that this warrants further study.

The authors thank Dr Thomas Stapleton of Lane End, High Wycombe, for his support and encouragement.

- 2 BOSTID Researchers. The epidemiology of acute respiratory tract infection in young children: comparison of findings from several developing countries. *Rev Infect Dis* 1990; 12 (suppl 8): S870-88.
- 3 Berman S. Epidemiology of acute respiratory infections in children of developing countries. *Rev Infect Dis* 1991; 13 (suppl 6): S454-62.
- 4 Ghafoor A, Nomani NK, Ishak Z, et al. Diagnoses of acute lower respiratory tract infections in children in Rawalpindi and Islamabad, Pakistan. *Rev Infect Dis* 1990; 12 (suppl 8): S907-14.
- 5 Korppi M, Leinonen M, Koskela M, Makela PH, Launiala K. Bacterial coinfection in children hospitalized with respiratory syncytial virus infections. *Pediatr Infect Dis J* 1989; 8: 687-92.
- 6 Hietala J, Uhari M, Tuokki H, Leinonen M. Mixed bacterial and viral infections are common in children. *Pediatr Infect Dis J* 1989; 8: 683-6.
- 7 Smith DW, Frankel LR, Mathers LH, Tang AT, Ariagno RL, Prober CG. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. *N Engl J Med* 1991; 325: 24-9.
- 8 Kong Xiao-Tang, Fang HT. Rapid diagnosis of respiratory syncytial virus infection by IgM antibody capture assay. *Journal of Harbin Medical University* 1989; 23: 172.
- 9 Meurman O, Sarkkinen H, Ruuskanen O, Hanninen P, Halonen P. Immunoglobulin class-specific antibody response in RSV infection measured by enzyme immunoassay. *J Med Virol* 1984; 14: 67-72.
- 10 Hornsleth A, Friis B, Grauballe PC, Krasilnikof PA. Detection by ELISA of IgA and IgM antibodies in serum in primary lower RSV infection. *J Med Virol* 1984; 13: 149-61.
- 11 Sutherland S, Briggs JD. The detection of antibodies to CMV in the sera of renal transplant patients by IgM antibody capture assay. *J Med Virol* 1983; 11: 147-59.
- 12 Shen-Sheng L, Hong J, Fang HG. *Rapid diagnosis of RSV infection: application of IgM antibody capture assay*. Shanghai: Virology Laboratory, Shanghai Institute for Pediatric Research [in Chinese].
- 13 Wu BJ, Huang WX, Yu CP, Zhou XB, Zhang SL, Yang RQ. *Pharmacology of Chinese herbs*. Beijing: People's Health Publication Corporation, 1983.
- 14 Jiang MX, Yang ZC, Yie YW, Zhang PR, Jing JZ, Shun JJ. *Pharmacology*. 2nd Ed. Beijing: People's Health Publication Corporation, 1984: 398.
- 15 Bruhn FW, Yeager AS. Respiratory syncytial virus in early infancy: circulating antibody and the severity of infection. *Am J Dis Child* 1977; 131: 145-8.
- 16 Zhang XL, Zhang ZL, Chen RZ. Laboratory research on the effect of Shuanghuanglian injection on respiratory syncytial virus. *Chinese Journal of Microorganism Immunology* 1988; 8: 263.
- 17 Xu KJ, Yang XH, Hu JR, Lu YC, Zhang HJ. *Research on Chinese Herbal Medicine* 1987; 2: 1.
- 18 Zhang Z, Wang Z, Cao Y, Zhu Z, Liu Y, Lin L. Acute respiratory infections in childhood in Beijing: an etiological study of pneumonia and bronchiolitis. *Chin Med J [Engl]* 1986; 99: 695-702.
- 19 Heycock JB, Noble TC. 1,230 cases of acute bronchiolitis in infancy. *BMJ* 1962; ii: 879-81.
- 20 Hall CB, Powell KP, Schnabel KC, Gala CL, Pincus PH. Risk of secondary bacterial infection in infants hospitalized with respiratory syncytial viral infection. *J Pediatr* 1988; 113: 266-71.
- 21 Arimasu O. Clinical studies on the secondary bacterial infection in RSV infection in children. *Kansenshogaku-Zasshi* 1989; 63: 248-55.